Bachem stock holds near 52-week high after strong half-year figures

Published on 09/20/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem stock closed at 78.70 CHF on September 18, 2026 on SIX, about 5.3 percent below its 52-week high after investors digested strong first-half 2026 results. The company’s market capitalization stood at 5.77 billion CHF as of September 17, 2026, underscoring the biotech group’s expanded valuation.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem Holding AG stock (ISIN CH0012530207) closed at 78.70 CHF on September 18, 2026 on the SIX Swiss Exchange, leaving the shares about 5.3 percent below their 52-week high of 83.25 CHF as investors continued to react to strong half-year 2026 figures.

Half-year 2026 figures underpin Bachem stock

According to Ad-hoc-news, investors focused on Bachem’s strong first-half 2026 performance, which the company reported recently and which now represents the latest available interim results for the peptide manufacturer.

As summarized by Ad-hoc-news, the first-half 2026 numbers marked a clear improvement versus the prior year, and the market has rewarded this with a valuation close to the 52-week high and significantly above the 52-week low.

The same overview notes that the 52-week trading range of Bachem stock currently runs between a low of 48.52 CHF and a high of 83.25 CHF, illustrating how far the shares have recovered from earlier weakness to reach the current level at 78.70 CHF.

Price level, trading range and market capitalization

Per data cited by Ad-hoc-news, Bachem shares traded at 78.15 CHF at 16:28 local time on September 18, 2026 on SIX, up 0.3% intraday, before closing at 78.70 CHF, which represented a gain of 1.0% versus the previous session.

On September 17, 2026, the same price snapshot from Ad-hoc-news based on finanzen.ch data shows a closing price of 77.95 CHF with a trading volume of 112,143 shares and a market capitalization of 5.77 billion CHF.

With the September 18, 2026 closing price of 78.70 CHF, Bachem stock on the SIX Swiss Exchange is trading clearly above its 52-week low of 48.52 CHF and about 5.3% below the 52-week high of 83.25 CHF, positioning the shares in the upper part of their recent range.

Investor takeaway on valuation and momentum

For investors, the combination of a closing price near the 52-week high and a market capitalization of 5.77 billion CHF as of September 17, 2026 suggests that the market is pricing in continued growth in Bachem’s peptide and active pharmaceutical ingredient business.

The modest day-to-day move from 77.95 CHF on September 17, 2026 to 78.70 CHF on September 18, 2026, a gain of 1.0%, indicates a steady upward trend rather than a sudden spike, which can be attractive for long-term holders looking for consistent performance.

Because the first-half 2026 report is the most recent interim period, investors will likely watch closely how the next set of figures compares, particularly whether revenue and earnings can continue to grow fast enough to justify the current valuation near the top of the 52-week band.

Stock price snapshot on SIX

As of the last completed trading day on September 18, 2026, Bachem stock traded at 78.70 CHF on the SIX Swiss Exchange, with the price sitting between the 52-week low of 48.52 CHF and the 52-week high of 83.25 CHF and supported by a market capitalization of 5.77 billion CHF as of September 17, 2026.